Study on the Effectiveness and Safety of Nizubaglustat in Patients with Niemann-Pick Type C, GM1, or GM2 Gangliosidosis
- Substances:Nizubaglustat
Portugal- Participants:0–17 years · 18–64 years
- Substances:Nizubaglustat
- Sponsor:Azafaros B.V.
Rare diseases
Investigational molecules
Locations
Clinical trials in Portugal – page 16824 clinical trials in Portugal across 20 research sites in 48 cities. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
PortugalStudy on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk
PortugalStudy on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia
PortugalStudy on Abatacept for Predicting Treatment Response in Patients with Early Rheumatoid Arthritis
PortugalStudy on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis
PortugalStudy on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease
PortugalStudy on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia
PortugalStudy on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease
PortugalStudy on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors
PortugalStudy of Durvalumab for Patients with Early Stage or Locally Advanced Non-Small Cell Lung Cancer Not Suitable for Surgery
PortugalStudy of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)
PortugalStudy on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns
PortugalWhere most of the country's trials are run
Shares are of these cities' trials together.
48 cities, A–Z – pick yours to filter the trials
What the registry says about research in the country
Portugal is actively engaged in clinical trials across a broad spectrum of oncological conditions. Research focuses on both solid tumors and hematological malignancies, with significant attention to non-small cell lung cancer, breast cancer, and various forms of lymphoma. Trials investigate novel immunotherapies, targeted therapies, and combination treatment regimens aimed at improving survival outcomes and quality of life for patients with advanced or metastatic disease.
The research landscape emphasizes precision medicine approaches, evaluating therapies based on biomarker expression and genomic alterations. Studies explore both first-line treatments and options for patients who have progressed on standard therapies, reflecting the comprehensive nature of cancer care development in the country.
A substantial portion of clinical research in Portugal addresses autoimmune disorders and chronic inflammatory conditions. Trials examine novel therapeutic agents for rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The focus extends to understanding disease mechanisms and developing targeted interventions that modulate immune responses.
Research efforts prioritize both induction and maintenance therapies, with particular attention to achieving clinical remission and improving long-term disease control. Studies also evaluate the safety and efficacy of biological agents and small molecule inhibitors in diverse patient populations.
Clinical trials addressing cardiovascular conditions represent a significant area of medical research in Portugal. Studies focus on heart failure, atrial fibrillation, acute coronary syndromes, and prevention of cardiovascular events in high-risk populations. Research encompasses both acute interventions and long-term management strategies aimed at reducing morbidity and mortality.
Investigations include novel anticoagulants, antiplatelet agents, and therapies targeting specific cardiac pathologies. The research also addresses atherosclerotic cardiovascular disease in patients with metabolic comorbidities and chronic kidney disease.
Portugal participates in extensive research on neurological conditions, with particular emphasis on multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Trials evaluate disease-modifying therapies, symptomatic treatments, and interventions aimed at slowing disease progression. Studies also address rare neurological conditions and epileptic disorders.
Research initiatives explore novel mechanisms of action, including immunomodulatory approaches and therapies targeting neuroinflammation. Trials also investigate treatments for frontotemporal dementia, amyotrophic lateral sclerosis, and other progressive neurological conditions.
Clinical trials focusing on respiratory tract diseases address conditions ranging from chronic obstructive pulmonary disease to interstitial lung diseases. Research evaluates treatments for asthma, cystic fibrosis, and pulmonary arterial hypertension, with emphasis on improving lung function and quality of life for patients with chronic respiratory conditions.
Studies investigate both anti-inflammatory therapies and disease-modifying agents, including novel formulations and delivery methods. Research also addresses bronchiectasis and respiratory complications in patients with underlying systemic conditions.
Portugal contributes to research on metabolic diseases and endocrine disorders, with significant focus on type 2 diabetes, obesity, and related cardiovascular complications. Trials evaluate therapies for non-alcoholic steatohepatitis, hypertriglyceridemia, and rare metabolic conditions. The research emphasizes integrated approaches addressing multiple aspects of metabolic syndrome.
Studies explore novel therapeutic agents including GLP-1 receptor agonists and combination therapies targeting multiple metabolic pathways. Research also addresses endocrine conditions such as hypoparathyroidism and congenital adrenal hyperplasia.
Clinical research addressing kidney diseases encompasses both acute and chronic conditions. Trials focus on chronic kidney disease, IgA nephropathy, and complications such as secondary hyperparathyroidism. Research evaluates interventions to slow disease progression, manage complications, and improve outcomes for patients requiring dialysis or transplantation.
Studies investigate therapies targeting inflammation, fibrosis, and immune-mediated kidney damage. Research also addresses the management of hyperkalemia and anemia associated with chronic kidney disease.
Portugal participates in trials addressing various skin diseases, with particular focus on atopic dermatitis, psoriasis, and hidradenitis suppurativa. Research evaluates both systemic and topical therapies aimed at controlling inflammation, reducing symptoms, and improving skin appearance. Studies also address rare genetic skin conditions and immune-mediated dermatoses.
Research emphasizes targeted immunomodulatory therapies and novel treatment approaches for conditions with significant impact on quality of life. Trials also investigate treatments for prurigo nodularis, chronic spontaneous urticaria, and rare blistering disorders.
Clinical trials in hematology address both malignant and non-malignant blood disorders. Research focuses on acute myeloid leukemia, chronic lymphocytic leukemia, various lymphomas, and non-malignant conditions such as immune thrombocytopenia and hemophilia. Studies evaluate novel cellular therapies, targeted agents, and supportive care interventions.
Research includes investigations of CAR-T cell therapies, bispecific antibodies, and novel combinations of established agents. Trials also address myelofibrosis, polycythemia vera, and other myeloproliferative neoplasms.
Portugal contributes to clinical research on eye diseases, particularly conditions affecting the retina and macula. Trials evaluate treatments for age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Research aims to preserve and improve vision while reducing treatment burden for patients with chronic ocular conditions.
Studies investigate novel anti-VEGF agents, extended dosing regimens, and combination therapies. Research also addresses retinopathy of prematurity and rare genetic eye diseases affecting pediatric populations.
Clinical trials in Portugal address numerous rare diseases and genetic conditions, reflecting a commitment to advancing treatments for underserved patient populations. Research encompasses lysosomal storage disorders, metabolic diseases, and rare forms of muscular dystrophy and connective tissue disorders.
Studies evaluate enzyme replacement therapies, gene therapies, and novel approaches to managing disease manifestations. Research also addresses hereditary angioedema, alpha-1 antitrypsin deficiency, and rare forms of amyloidosis.
Portugal participates in research addressing various infectious diseases, including bacterial infections, viral diseases, and emerging pathogens. Trials evaluate novel antimicrobial agents, antiviral therapies, and preventive strategies. Research also addresses complications of infections and long-term sequelae.
Studies investigate both treatment and prevention approaches, including vaccine development and immunomodulatory therapies. Research also addresses Clostridioides difficile infection and management of infections in immunocompromised patients.
Clinical research on digestive system diseases encompasses conditions affecting the entire gastrointestinal tract. Beyond inflammatory bowel diseases, trials address gastroesophageal reflux disease, eosinophilic esophagitis, and functional gastrointestinal disorders. Research evaluates both pharmacological interventions and procedural approaches.
Studies investigate novel anti-inflammatory agents, prokinetic therapies, and approaches to managing chronic symptoms. Research also addresses complications of gastrointestinal diseases and quality of life improvements.
Portugal engages in research on musculoskeletal diseases beyond traditional rheumatological conditions. Trials address osteoarthritis, tendinopathies, and rare bone disorders. Research evaluates interventions for pain management, functional improvement, and disease modification in conditions affecting bones, joints, and connective tissues.
Studies explore regenerative therapies, targeted biologics, and novel approaches to managing chronic pain and disability. Research also addresses pediatric musculoskeletal conditions and growth disorders.
Clinical trials addressing mental health conditions focus on major depressive disorder, schizophrenia, and obsessive-compulsive disorder. Research evaluates novel therapeutic approaches for treatment-resistant conditions and investigates interventions for specific symptom clusters. Studies also address behavioral manifestations of neurodegenerative diseases.
Research emphasizes both pharmacological and non-pharmacological interventions, with attention to improving quality of life and functional capacity. Trials also investigate treatments for nicotine addiction and behavioral symptoms in dementia.
Tell us about your condition – we search every trial in Europe and connect you with the right site.